Mayne Pharma Group Limited Stock

Equities

MYX

AU000000MYX0

Pharmaceuticals

Market Closed - Australian S.E. 02:10:52 2024-06-03 am EDT 5-day change 1st Jan Change
5.01 AUD -0.60% Intraday chart for Mayne Pharma Group Limited -2.91% -18.54%
Sales 2024 * 383M 254M Sales 2025 * 426M 283M Capitalization 409M 272M
Net income 2024 * -88M -58.45M Net income 2025 * -19M -12.62M EV / Sales 2024 * 0.86 x
Net cash position 2024 * 79.89M 53.07M Net cash position 2025 * 53.05M 35.24M EV / Sales 2025 * 0.84 x
P/E ratio 2024 *
-4.65 x
P/E ratio 2025 *
-20.7 x
Employees 967
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.60%
1 week-2.91%
Current month-0.60%
1 month-32.02%
3 months-26.43%
6 months-7.73%
Current year-18.54%
More quotes
1 week
4.84
Extreme 4.84
5.20
1 month
4.84
Extreme 4.84
7.43
Current year
4.84
Extreme 4.84
7.46
1 year
2.75
Extreme 2.75
7.46
3 years
0.22
Extreme 0.22
8.50
5 years
0.22
Extreme 0.22
12.90
10 years
0.22
Extreme 0.22
42.20
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-09-30
Director of Finance/CFO - 22-08-28
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 70 18-05-29
Director/Board Member 59 18-06-27
Chief Executive Officer - 22-09-30
More insiders
Date Price Change Volume
24-06-03 5.01 -0.60% 168 919
24-05-31 5.04 +0.40% 205,122
24-05-30 5.02 +0.80% 146,364
24-05-29 4.98 -2.54% 259,013
24-05-28 5.11 -0.97% 571,845

Delayed Quote Australian S.E., June 03, 2024 at 02:10 am EDT

More quotes
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.04 AUD
Average target price
6.89 AUD
Spread / Average Target
+36.71%
Consensus